Loading data…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$90.7M net income for the year ended December 26, 2025. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| December 28, 2024 – December 26, 2025 | $4,322,300,000 | February 19, 2026 | 10-K ↗ |
| December 30, 2023 – December 27, 2024 | $4,280,200,000 | February 19, 2026 | 10-K ↗ |
| December 31, 2022 – December 29, 2023 | $4,320,700,000 | February 19, 2026 | 10-K ↗ |
| January 1, 2022 – December 30, 2022 | $4,442,300,000 | February 24, 2025 | 10-K ↗ |
| January 2, 2021 – December 31, 2021 | $4,252,000,000 | February 26, 2024 | 10-K ↗ |
| December 28, 2019 – January 1, 2021 | $4,202,300,000 | February 22, 2023 | 10-K ↗ |
| December 29, 2018 – December 27, 2019 | $4,489,000,000 | February 23, 2022 | 10-K ↗ |
| December 30, 2017 – December 28, 2018 | $4,493,900,000 | February 24, 2021 | 10-K ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:Revenues · Retrieved October 13, 2026
Response SHA-256: c09e2826f6e6443ced7d2a6a4a21ebb55b8c3abe803b38e69360a0c84ebcdc56
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.